-
Chinese experience goes global——Professor Zhao Weilai shared valuable experience of CAR-T treatment at the APBMT conference
Time of Update: 2021-11-04
Professor Zhao Weilai shared the treatment and management of two Chinese DLBCL patients receiving CAR-T cell therapy.
Another Chinese patient shared by Professor Zhao Weilai is a 76-year-old female diagnosed with Non-GCB DLBCL, Ann Arbor stage IIIA, IPI score of 2, and a previous history of Sjogren’s syndrome .
-
An article to understand the individualized treatment strategy for Waldenstrom's macroglobulinemia
Time of Update: 2021-11-04
A study using allele-specific polymerase chain reaction (AS-PCR) to detect the mutation status of MYD88 in bone marrow cells sorted by CD19 showed that the remission rate of MYD88WT patients treated with ibrutinib was lower .
-
Blood Peking University Zhang Xiaohui's team discovers a potential new treatment for immune thrombocytopenia
Time of Update: 2021-11-04
This study aims to compare all-trans retinoic acid (ATRA) plus low-dose rituximab (LD-RTX) and LD-RTX monotherapy in patients with corticosteroid resistance or recurrent immune thrombocytopenia (ITP) The efficacy and safety .
-
Innovate with potential, and move forward with determination—individualized preventive treatment under the guidance of PK in the digital age
Time of Update: 2021-11-04
A retrospective observational study, using PK software to perform PK detection on 6 patients with hemophilia, simulate the Bayesian curve, and develop individualized prevention and treatment plans .
Another study included 27 patients with severe hemophilia A who were treated with rAHF-PFM and used PK software for PK-guided individualized preventive treatment .
-
Professor Liu Ting: New progress in the treatment of acute lymphoblastic leukemia
Time of Update: 2021-11-04
In this case, the application of small molecule targeted drugs and new antibody drugs, and the rise of cellular immunotherapy CAR-T therapy have brought about With more treatment options, the emergence of these drugs makes MRD-positive patients, and even relapsed and refractory patients, have more opportunities to obtain CMR and achieve MRD-negative, so as to achieve long-term survival .
-
Hematol Oncol: The key role of high-mobility A histone in hematological malignancies
Time of Update: 2021-11-03
It is worth noting that HMGA-based therapies may have a wide range of applications and can be used to treat hematological malignancies and cancers of different sources that overexpress these proteins .
-
J Hematol Oncol: The response of multiple myeloma patients to COVID-19 mRNA vaccination is conservative but impaired
Time of Update: 2021-11-03
COVID-19 Compared with the control group, the anti-spinous IgG levels of multiple myeloma patients decreased, but the proportion of patients who achieved a humoral response was high (89% vs 97%, the control group) .
-
Clinicians question the results of glycosylated hemoglobin, what's wrong?
Time of Update: 2021-11-03
Therefore, the patient in this case has a history of diabetes, high blood sugar and high urine glucose, but the result of glycosylated hemoglobin is negative .
-
J Thromb Haemost: Growth differentiation factor-15 can be used to predict bleeding events in cancer patients
Time of Update: 2021-11-03
GDF-15 concentration was also significantly related to clinically relevant non-major bleeding (adjusted HR of 1.
This shows that this study shows that GDF-15 can predict bleeding events in cancer patients receiving thromboprophylaxis .
This study shows that GDF-15 can predict bleeding events in cancer patients receiving thromboprophylaxis .
-
Is the drop in platelets really caused by drugs?
Time of Update: 2021-11-03
On February 18, the clinical round showed that the continued decline of platelets was considered a serious infection, and the possibility of drug causes could not be ruled out .
-
Lancet Oncol: Efficacy and safety of IDH2 inhibitor Enasidenib combined with azacitidine in the treatment of IDH2 mutant acute myeloid leukemia
Time of Update: 2021-11-03
In summary, compared with azacitidine monotherapy, Enasidenib combined with azacitidine is well tolerated in newly diagnosed IDH2 mutant acute myeloid leukemia patients, and the overall remission rate is significantly improved, suggesting that The program can improve the clinical prognosis of such patients .
-
BMJ: Heparin treatment can reduce the risk of death in hospitalized patients with moderate new coronary pneumonia with elevated D dimer levels
Time of Update: 2021-11-03
465 adult patients with Covid-19 and elevated D-dimer levels participated in the study and were randomized to receive therapeutic doses of heparin ( n=228) or prophylactic dose heparin (n=237) treatment, continued until discharge, 28th day or death .
-
Thyroid: The effect of thyroid function on hemostasis, coagulation and fibrinolysis systems
Time of Update: 2021-11-03
Methods: In a two-sample Mendelian randomization (MR) study with genome-wide association variants, we evaluated genetically predicted hypothyroidism (N=134,641), normal range thyroid-stimulating hormone (TSH; N=54,288) ) And free thyroxine (fT4) (N=49,269), hyperthyroidism (N=51,823) and positive thyroid peroxidase antibody (N=25,821) .
-
Nutrients: In patients with chronic statin therapy, octacosanol supplementation can affect PCSK9 levels and restore its physiological relationship with LDL-C
Time of Update: 2021-11-02
Compared with the baseline, the serum apolipoprotein B100 level increased significantly after 8 weeks in the dietary supplement group (but no clinical correlation), but the effect disappeared after 13 weeks (the main influencing factor was time, P = 0.
-
CCSC: Rising to the challenge, the application of CAR-T in the treatment of refractory lymphoma
Time of Update: 2021-10-23
In this session, Professor Robin from King’s College Hospital in London shared a speech entitled "Yescarta for Relapsed DLBCL: Real World Experience and lessons learnt" .
At present, Akirensai injection is suitable for patients with refractory or relapsed LBCL after second-line chemotherapy or transplantation treatment .
-
2021 CSCO Professor Li Yexiong talks about the important role of radiotherapy in the treatment of indolent lymphoma
Time of Update: 2021-10-23
The researchers analyzed the SEER database of patients with stage I gastric MALT lymphoma from 1993 to 2014 and found that the 5-year OS rate and 5-year disease-specific survival (DSS) rate of patients receiving radiotherapy were higher than those of patients in the chemotherapy group .
-
Professor Huang Xiaojun: Looking at the development of AML treatment models from the release of China's new guidelines
Time of Update: 2021-10-23
[WeiKeLai® is here] Optimize the diagnosis and treatment model of AML and explore the application of Vinekalla in China Click Read the full article to learn more about BCL-2 inhibitors Genentech Announces FDA Grants VenclextaAccelerated Approval for People With Newly-Diagnosed Acute Myeloid Leukemia or Those Who Are Ineligible For Intensive Induction Chemotherapy.
-
CCSC: Looking around the world, knowing the international vision of CAR-T in the treatment of lymphoma
Time of Update: 2021-10-22
This conference is fortunate to invite Professor Song Yuqin from Peking University Cancer Hospital, Professor Sattva Neelapu from MD Anderson Cancer Center and many top domestic experts as speakers and discussion guests, focusing on cutting-edge topics in the field of CAR-T cell therapy.
-
Professor Liu Qifa: The guideline treatment pattern is changing with each passing day, and the AML treatment concept is constantly improving
Time of Update: 2021-10-22
Of particular importance is that the new version of the guidelines has increased the usage, dosage and combination of BCL-2 inhibitor venecola, increased targeted drugs geritinib and sorafenib for the treatment of patients with FLT3 mutations, and increased IDH1 Inhibitors, IDH2 inhibitors and other related content .
-
2021 CSCO Expert Interview｜Professor Cai Qingqing talks about the treatment progress of diffuse large B-cell lymphoma
Time of Update: 2021-10-22
In addition, last year’s ASCO and ESMO meeting reported the results of a phase I/II study of CD19/CD22 dual-targeting CAR-T cells (AUTO3) combined with PD-1 monoclonal antibody for the treatment of R/R DLBCL, using different doses of AUTO3 alone or in combination The ORR of pembrolizumab-treated patients was 68%, the CR rate was 54%, and the duration of complete remission was long.
